Matches in SemOpenAlex for { <https://semopenalex.org/work/W2810731026> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2810731026 abstract "To confirm non-inferiority of biphasic insulin aspart 30 (BIAsp 30) plus metformin to BIAsp 30 in lowering glycated haemoglobin (HbA1c) in Chinese patients with inadequately controlled type 2 diabetes using oral antidiabetic drugs.In this 16-week, prospective, randomized, open-label, multicentre, parallel-controlled study, patients aged 18-79 years with HbA1c ≥7% were randomized to BIAsp 30 plus metformin (n = 130) or BIAsp 30 (n = 127). Initially, 500 mg metformin was administered twice daily and BIAsp 30 was administered at 0.2-0.3 U/kg/d. Changes in HbA1c % from baseline to week 16 as well as secondary and safety endpoints were assessed.In total, 83.66% of patients in the BIAsp 30 plus metformin (n = 110) and the BIAsp 30 (n = 105) groups completed the study. Mean (±standard deviation) change in HbA1c from baseline to endpoint was -1.74 ± 1.64% and -1.32 ± 2.05% with BIAsp 30 plus metformin and BIAsp 30, respectively. Least squares mean treatment difference was -0.67% (95% CI, -1.06; -0.28). The upper limit of the 95% CI was <0.4 (non-inferiority margin). A significantly higher proportion of individuals reached HbA1c <7% with BIAsp 30 plus metformin than with BIAsp 30 (53.15% vs 35.19%; P = 0.0074). At endpoint, daily BIAsp 30 dose (P < 0.001) and weight gain were significantly lower (P < 0.05) in the BIAsp 30 plus metformin group compared with the BIAsp 30 group. No between-group differences in number of hypoglycaemic events were observed.BIAsp 30 plus metformin was non-inferior to BIAsp 30 in safely reducing HbA1c in this study." @default.
- W2810731026 created "2018-07-10" @default.
- W2810731026 creator A5009058483 @default.
- W2810731026 creator A5012578672 @default.
- W2810731026 creator A5018073672 @default.
- W2810731026 creator A5025384599 @default.
- W2810731026 creator A5037989560 @default.
- W2810731026 creator A5063227916 @default.
- W2810731026 date "2018-08-02" @default.
- W2810731026 modified "2023-10-15" @default.
- W2810731026 title "A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral anti" @default.
- W2810731026 cites W1857972531 @default.
- W2810731026 cites W1939677357 @default.
- W2810731026 cites W1989742048 @default.
- W2810731026 cites W1990970897 @default.
- W2810731026 cites W1996580481 @default.
- W2810731026 cites W2001387623 @default.
- W2810731026 cites W2020805583 @default.
- W2810731026 cites W2037057866 @default.
- W2810731026 cites W2060495866 @default.
- W2810731026 cites W2096999369 @default.
- W2810731026 cites W2098898873 @default.
- W2810731026 cites W2134907909 @default.
- W2810731026 cites W2136642766 @default.
- W2810731026 cites W2146514310 @default.
- W2810731026 cites W2156888511 @default.
- W2810731026 cites W2158789685 @default.
- W2810731026 cites W2188846692 @default.
- W2810731026 cites W2340898396 @default.
- W2810731026 cites W2486646922 @default.
- W2810731026 cites W2527670279 @default.
- W2810731026 cites W2728898687 @default.
- W2810731026 cites W2731349674 @default.
- W2810731026 cites W2766576618 @default.
- W2810731026 cites W4256525495 @default.
- W2810731026 doi "https://doi.org/10.1111/dom.13454" @default.
- W2810731026 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29961975" @default.
- W2810731026 hasPublicationYear "2018" @default.
- W2810731026 type Work @default.
- W2810731026 sameAs 2810731026 @default.
- W2810731026 citedByCount "2" @default.
- W2810731026 countsByYear W28107310262021 @default.
- W2810731026 countsByYear W28107310262022 @default.
- W2810731026 crossrefType "journal-article" @default.
- W2810731026 hasAuthorship W2810731026A5009058483 @default.
- W2810731026 hasAuthorship W2810731026A5012578672 @default.
- W2810731026 hasAuthorship W2810731026A5018073672 @default.
- W2810731026 hasAuthorship W2810731026A5025384599 @default.
- W2810731026 hasAuthorship W2810731026A5037989560 @default.
- W2810731026 hasAuthorship W2810731026A5063227916 @default.
- W2810731026 hasBestOaLocation W28107310261 @default.
- W2810731026 hasConcept C126322002 @default.
- W2810731026 hasConcept C134018914 @default.
- W2810731026 hasConcept C2777180221 @default.
- W2810731026 hasConcept C2779306644 @default.
- W2810731026 hasConcept C2780323712 @default.
- W2810731026 hasConcept C555293320 @default.
- W2810731026 hasConcept C71924100 @default.
- W2810731026 hasConceptScore W2810731026C126322002 @default.
- W2810731026 hasConceptScore W2810731026C134018914 @default.
- W2810731026 hasConceptScore W2810731026C2777180221 @default.
- W2810731026 hasConceptScore W2810731026C2779306644 @default.
- W2810731026 hasConceptScore W2810731026C2780323712 @default.
- W2810731026 hasConceptScore W2810731026C555293320 @default.
- W2810731026 hasConceptScore W2810731026C71924100 @default.
- W2810731026 hasLocation W28107310261 @default.
- W2810731026 hasLocation W28107310262 @default.
- W2810731026 hasOpenAccess W2810731026 @default.
- W2810731026 hasPrimaryLocation W28107310261 @default.
- W2810731026 hasRelatedWork W1976422603 @default.
- W2810731026 hasRelatedWork W1978360972 @default.
- W2810731026 hasRelatedWork W1996010611 @default.
- W2810731026 hasRelatedWork W2032746366 @default.
- W2810731026 hasRelatedWork W2071602074 @default.
- W2810731026 hasRelatedWork W2084730744 @default.
- W2810731026 hasRelatedWork W2166498497 @default.
- W2810731026 hasRelatedWork W2896883278 @default.
- W2810731026 hasRelatedWork W3130171081 @default.
- W2810731026 hasRelatedWork W1920632900 @default.
- W2810731026 isParatext "false" @default.
- W2810731026 isRetracted "false" @default.
- W2810731026 magId "2810731026" @default.
- W2810731026 workType "article" @default.